Respiratory therapist

SEIU-UHW: Healthcare Workers to Set Up Danger Zones to Protest Short-Staffing at Sutter Hospitals Across Northern CA

Retrieved on: 
Monday, July 5, 2021
Work, Human activities, Human behavior, Healthcare in California, Sutter Health, Personal protective equipment, Health professional, Caregiver, Respiratory therapist

"While Sutter has been driving up costs, they've been driving down the quality of care, staffing and safety at our hospitals.

Key Points: 
  • "While Sutter has been driving up costs, they've been driving down the quality of care, staffing and safety at our hospitals.
  • Workers are getting run ragged with no time for breaks, and patients are suffering with long wait times for the care they need," said Stefanye Sartain, Respiratory Therapist, Sutter Delta Medical Center.
  • Healthcare workers will set up a danger zone with large signs and other visuals,
    caregivers in their uniforms, PPE and safety gear.
  • They will hold a rally, give speeches, and hold signs in protest of Sutter Health's understaffing, long patient wait times and worker safety issues.

Encore Healthcare Announces Staggering Results in New Nexus TeleRespiratory Care Pilot Using Data to Predict when Oxygen/Nebulizer Patients Need Non-Invasive Ventilation (NIV) Before Hospitalizations Happen

Retrieved on: 
Friday, June 11, 2021
Medicine, Health sciences, Clinical medicine, Respiratory therapy, Medical equipment, Dosage forms, Aerosols, Nebulizer, Oxygen, Oxygen therapy, Chronic obstructive pulmonary disease, Respiratory therapist

LIVINGSTON, Tenn., June 11, 2021 /PRNewswire/ --Encore Healthcare announces staggering results from their new oxygen and nebulizer management Nexus TeleRespiratory Care model.

Key Points: 
  • LIVINGSTON, Tenn., June 11, 2021 /PRNewswire/ --Encore Healthcare announces staggering results from their new oxygen and nebulizer management Nexus TeleRespiratory Care model.
  • In the initial pilot with a national HME provider Encore identified 12.5% of patients on oxygen/nebulizers needed additional services including medications, NIV and High Frequency Chest Wall Oscillation (HFCWO).
  • These results are an example of how data can drive better patient outcomes and revenue to HME providers at the same time.
  • The Nexus platform aligns HME respiratory providers across traditional boundaries while increasing provider productivity and clinical outcomes with their Ventilator/High-Risk COPD patients.

Vapotherm to Host First Investor Day

Retrieved on: 
Wednesday, June 9, 2021
Biotechnology, Medical devices, Manufacturing, Other Manufacturing, Health, Medical specialties, Medicine, Health care, Medical emergencies, Respiratory therapy, Respiratory diseases, Diving medicine, Hypercapnia, Ventilator, Vapotherm, Respiratory therapist, Hypoxemia

Vapotherm, Inc. (NYSE: VAPO) is a publicly traded developer and manufacturer of advanced respiratory technology based in Exeter, New Hampshire, USA.

Key Points: 
  • Vapotherm, Inc. (NYSE: VAPO) is a publicly traded developer and manufacturer of advanced respiratory technology based in Exeter, New Hampshire, USA.
  • Over 2.8 million patients have been treated with the use of Vapotherm high velocity therapy systems.
  • Vapotherm high velocity therapy is mask-free noninvasive ventilatory support and is a front-line tool for relieving respiratory distressincluding hypercapnia, hypoxemia, and dyspnea.
  • Vapotherm routinely posts important information for investors on the Investor Relations section of its website, http://investors.vapotherm.com/ .

Expressing Gratitude to Respiratory Therapy Professionals

Retrieved on: 
Friday, June 4, 2021
Health care, Medical specialties, Health, Respiratory therapy, American Association for Respiratory Care, Respiratory therapist, Severe acute respiratory syndrome, Influenza A virus subtype H1N1, Health professional, College of Respiratory Therapists of Ontario, College and Association of Respiratory Therapists of Alberta

Since the days of 1918 Flu, through pulmonary tuberculosis, SARS and H1N1, and even Katrina, respiratory therapy has been there for them all.

Key Points: 
  • Since the days of 1918 Flu, through pulmonary tuberculosis, SARS and H1N1, and even Katrina, respiratory therapy has been there for them all.
  • Because of this, the American Association for Respiratory Care (AARC) developed a PSA video to highlight the profession and the work respiratory therapists do each day.
  • It also serves as a call to express our gratitude to these health care professionals, asking our community to take time to thank a respiratory therapist.
  • Like many health care professionals working on the front lines of the pandemic, respiratory therapists worked tirelessly and selflessly to help patients everywhere.

Children's Minnesota NICU at Mercy Hospital expands services to help high-risk mothers deliver closer to home

Retrieved on: 
Tuesday, June 1, 2021
Medical specialties, Health, Neonatology, Infancy, Intensive care medicine, Neonatal intensive care unit, Nursing, Preterm birth, Children's Hospital Colorado, Maternal–fetal medicine, Respiratory therapist, University of Missouri Women's and Children's Hospital

The Mother Baby Center at Mercy Hospital also offers:

Key Points: 
  • The Mother Baby Center at Mercy Hospital also offers:
    Experts in the care of high-risk pregnancies (maternal-fetal medicine specialists) with a newly expanded, state-of-the art space, providing ultrasounds and 24/7 inpatient consultations.
  • Neonatologists, nurses, nurse practitioners and respiratory therapists who specialize in premature babies and critically ill newborns available 24/7.
  • In addition to the Level III NICU at Mercy Hospital in Coon Rapids, through Children's Minnesota, The Mother Baby Center offers high level neonatal expertise at its locations in Minneapolis and St. Paul .
  • Children's Minnesota is regularly ranked by U.S. News & World Report as a top children's hospital.

Dynarex Corporation Announces Premium Line of Respiratory Products--Dynarex Resp-O2™

Retrieved on: 
Tuesday, May 25, 2021
Respiratory therapist, Respirator, Disposable product

ORANGEBURG, N.Y., May 25, 2021 /PRNewswire/ -- Dynarex Corporation , a leading durable medical equipment and disposable medical products company, is pleased to announce its innovative new line of premium respiratory products Dynarex Resp-O2 .

Key Points: 
  • ORANGEBURG, N.Y., May 25, 2021 /PRNewswire/ -- Dynarex Corporation , a leading durable medical equipment and disposable medical products company, is pleased to announce its innovative new line of premium respiratory products Dynarex Resp-O2 .
  • Working closely with respiratory therapists and industry experts, Dynarex conducted in-depth research to develop a robust selection of high-quality respiratory products to serve the evolving needs of both patients and caregivers.
  • "In these challenging times, we recognize the growing demand for high-quality disposable supplies in the respiratory space," said Dynarex CEO Zalman Tenenbaum.
  • Dynarex is a leading medical supply company providing premium medical products and durable medical equipment at exceptional value for an unparalleled one-stop shopping experience.

Vapotherm to Participate in the William Blair 41st Annual Growth Stock Conference

Retrieved on: 
Tuesday, May 25, 2021
Health, Medical Supplies, Other Health, Medical devices, Medical specialties, Medicine, Clinical medicine, Respiratory therapy, Medical emergencies, Respiratory diseases, Ventilator, Hypercapnia, Vapotherm, Respiratory therapist

Vapotherm, Inc. (NYSE: VAPO), (Vapotherm or the Company), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy products, which are used to treat patients of all ages suffering from respiratory distress, today announced that its management team will be participating in the William Blair 41st Annual Growth Stock Conference on Tuesday, June 1, 2021 via webcast.

Key Points: 
  • Vapotherm, Inc. (NYSE: VAPO), (Vapotherm or the Company), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy products, which are used to treat patients of all ages suffering from respiratory distress, today announced that its management team will be participating in the William Blair 41st Annual Growth Stock Conference on Tuesday, June 1, 2021 via webcast.
  • Vapotherm, Inc. (NYSE: VAPO) is a publicly traded developer and manufacturer of advanced respiratory technology based in Exeter, New Hampshire, USA.
  • Over 2.8 million patients have been treated with the use of Vapotherm high velocity therapy systems.
  • Vapotherm high velocity therapy is mask-free noninvasive ventilatory support and is a front-line tool for relieving respiratory distressincluding hypercapnia, hypoxemia, and dyspnea.

Teleflex Signs Definitive Agreement to Sell Certain Respiratory Assets and Reaffirms Adjusted EPS Guidance

Retrieved on: 
Tuesday, May 18, 2021
Medicine, Medical terminology, Respiratory therapist, Teleflex, Spirometer, Minimally invasive procedure, Cardiology, Interventional cardiology, Non-invasive procedure

The Teleflex respiratory product lines that will be divested include oxygen and aerosol therapy, active humidification, non-invasive ventilation, and incentive spirometers, which generated $139 million in revenue in 2020.

Key Points: 
  • The Teleflex respiratory product lines that will be divested include oxygen and aerosol therapy, active humidification, non-invasive ventilation, and incentive spirometers, which generated $139 million in revenue in 2020.
  • We look forward to providing a full financial update to investors on our second quarter 2021 earnings call.
  • Our portfolio is diverse, with solutions in the fields of vascular access, interventional cardiology and radiology, anesthesia, emergency medicine, surgical, urology and respiratory care.
  • Teleflex employees worldwide are united in the understanding that what we do every day makes a difference.

Global Nebulizers (Pneumatic, Ultrasonic, Mesh) Market Report 2021: COVID-19 Impacts, Implications and Growth to 2025 & 2030 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 12, 2021
Medical devices, Health, Medicine, Health sciences, Health, Respiratory therapy, Medical equipment, Dosage forms, Aerosols, Nebulizer, Asthma, COVID-19, Respiratory disease, Respiratory therapist

b'The "Nebulizers Global Market Report 2021: COVID-19 Implications and Growth to 2030" report has been added to ResearchAndMarkets.com\'s offering.\nNebulizers Global Market Report 2021: COVID-19 Implications and Growth to 2030 covers this critical market and the impact on it from the COVID-19 virus.

Key Points: 
  • b'The "Nebulizers Global Market Report 2021: COVID-19 Implications and Growth to 2030" report has been added to ResearchAndMarkets.com\'s offering.\nNebulizers Global Market Report 2021: COVID-19 Implications and Growth to 2030 covers this critical market and the impact on it from the COVID-19 virus.
  • The market is expected to reach $1.55 billion in 2025 at a CAGR of 10.5%.\nThe nebulizer devices market consists of sales of nebulizers used in respiratory care for patients with respiratory diseases including asthma, cystic fibrosis and COPD.
  • There has been an increased use of albuterol inhalers in hospitals for Covid-19 and suspected Covid-19 patients to help with respiratory issues.
  • Rise in geriatric population is anticipated to propel the nebulizer market growth.\n'

ResBiotic, Inc. Raises $3M Seed Round and Announces Leadership Team

Retrieved on: 
Thursday, April 29, 2021
Bacteriology, Digestive system, Probiotic, Respiratory therapist, Innovation, Respiratory disease, Articles, Branches of biology

The proprietary probiotic blend has been shown to reduce neutrophilic inflammation in individuals with chronic respiratory conditions.

Key Points: 
  • The proprietary probiotic blend has been shown to reduce neutrophilic inflammation in individuals with chronic respiratory conditions.
  • "With strategic and manufacturing partners in place, the ResBiotic team is on track to bring our first product to market in early 2022.
  • "We\'re proud to be able to support a top notch team commercializing a critical innovation with the potential to transform standards of respiratory care.
  • "\nIn addition to the seed funding, Dr. Lal has established an elite leadership team .